Eucrates Biomedical Acquisition Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EUCR research report →
Price Chart
About the company
Eucrates Biomedical Acquisition Corp. currently lacks substantial business operations. Its primary objective is to execute a corporate transaction such as a merger, stock swap, asset purchase, equity acquisition, restructuring, or another comparable strategic alliance involving one or more enterprises.
- CEO
- Parag Phoolchand Saxena MBA, MS
- IPO
- 2020
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on EUCR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $42.23M
- P/E
- 5.40
- PEG
- -0.13
- P/S
- 0.00
- P/B
- 3.50
- EV/EBITDA
- -60.47
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 10.27%
- ROIC
- -5.63%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-699,000
- Net Income
- $5.54M+44.8%
- EPS
- $1.86+45.3%
- OCF Growth
- -25.5%
- FCF Growth
- -25.5%
- 52W High
- $10.25
- 52W Low
- $9.87
- 50D MA
- $10.11
- 200D MA
- $10.02
- Beta
- -0.07
- RSI (14)
- 34
- Avg Volume
- 1.66K
No earnings-call transcripts are available for EUCR yet.
- Free Float
- 37.7%
- Shares Outstanding
- 4.21M
- Float Shares
- 1.59M
of shares held by institutions
6 13F filers
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 24, 20 | SAXENA PARAG | other | 255,094 |
| Nov 24, 20 | PAPADOPOULOS STELIOS | other | 255,094 |
| Nov 24, 20 | Eucrates LLC | other | 255,094 |
| Oct 23, 20 | Vergetis Evangelos | other | 0 |
| Oct 23, 20 | Singhal Amitabh | other | 0 |
| Oct 23, 20 | Shapiro Nina B. | other | 0 |
| Oct 23, 20 | SAXENA PARAG | other | 0 |
| Oct 23, 20 | Sathe Shrikant | other | 0 |
| Oct 23, 20 | PAPADOPOULOS STELIOS | other | 0 |
| Oct 23, 20 | PAPADOPOULOS STELIOS | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our EUCR coverage
Recent articles, reports, and earnings notes.
No research on EUCR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EUCR report →